Ascites Market By Treatment Type (Diuretics, Large-Volume Paracentesis, Albumin Therapy, Transjugular Intrahepatic Portosystemic Shunt [TIPS], Implantable Pump Systems, Indwelling Drainage Catheters, Liver Transplantation, Investigational Therapies); By Disease Type (Cirrhotic Ascites, Malignant Ascites, Cardiac Ascites, Renal Ascites, Other Ascites Conditions); By End User (Hospitals, Liver Transplant Centers, Specialty Clinics, Ambulatory and Outpatient Care Centers, Home-Care Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Ascites Market: Recurring Fluid Management Creates a Procedure-Led Care Economy

The Global Ascites Market was valued at USD 1.56 billion in 2025 and is projected to reach USD 2.46 billion by 2032, expanding at a CAGR of 6.7% during 2026–2032, according to Strategic Market Research.

 

Ascites is the abnormal buildup of fluid in the abdominal cavity, most commonly caused by liver cirrhosis, but it may also occur with heart failure, kidney failure, or abdominal cancers. Common symptoms include abdominal swelling, rapid weight gain, bloating, pain, and shortness of breath. Management focuses on reducing sodium and fluid retention, removing excess fluid, and maintaining circulation and kidney function.

 

Standard treatment includes sodium restriction, spironolactone, furosemide, large-volume paracentesis with albumin, and the alfapump system. Spironolactone blocks aldosterone to increase sodium and water excretion while conserving potassium, whereas furosemide inhibits sodium reabsorption in the loop of Henle to promote diuresis. Paracentesis directly drains abdominal fluid, albumin maintains plasma oncotic pressure and circulating volume, and the alfapump transfers fluid into the bladder for urinary elimination. Investigational therapies include terlipressin, which improves circulation through vasoconstriction, docarpamine, which may enhance renal blood flow and sodium excretion, and PHIN-214, which is being studied for its effects on fluid balance and portal hypertension.

 

Ascites Marks the Point Where Liver Disease Becomes Resource Intensive

Ascites usually appears after chronic liver disease has moved into decompensation. The American Association for the Study of Liver Diseases estimates that 5%–10% of people with compensated cirrhosis develop ascites each year. Once ascites develops, five-year survival falls from approximately 80% to 30%. The decline reflects the added risk of bacterial infection, kidney dysfunction, electrolyte imbalance and malnutrition. 

This transition changes the commercial profile of liver disease. A patient who previously required periodic monitoring may begin needing repeated blood tests, ultrasound examinations, paracentesis, albumin infusions, antibiotics and specialist consultations. Ascites also increases referrals to interventional radiology, transplant programs and emergency departments.

The underlying liver-disease population remains large. A Global Burden of Disease analysis estimated 58.4 million incident cases, 1.43 million deaths and 46.4 million disability-adjusted life years from cirrhosis and other chronic liver diseases in 2021. From 2010 to 2021, incident cases increased by 18% and deaths increased by 7%. These figures are not specific to ascites, but they represent the population from which advanced fluid complications develop. 

Southeast Asia recorded the highest absolute burden in the same analysis, with approximately 14.8 million incident cases and 460,400 deaths in 2021. The Americas reported the largest increase in deaths between 2010 and 2021, at 22%. Regional demand for ascites management will therefore reflect both existing cirrhosis prevalence and the speed at which metabolic, alcohol-related and viral liver diseases progress. 

Commercial value is concentrated in recurrent and refractory disease. AASLD reported in 2025 that survival among patients with refractory ascites is approximately 50% at six months and 25% at one year. These patients may require drainage every few weeks, repeated albumin administration and frequent evaluation for infection, kidney injury, transplantation or advanced procedures. 

Beyond liver disease, ascites demand is reinforced by multiple systemic conditions that expand the addressable patient pool. Heart failure affects over 64 million people globally and 6.7 million in the United States, and rising prevalence is expected to increase fluid overload complications requiring diuretics, imaging, and in severe cases, drainage-based interventions. Malignant ascites accounts for roughly 10% of all cases and is most commonly associated with ovarian and gastrointestinal cancers, where median survival is only 5–7 months, creating sustained demand for palliative paracentesis and indwelling drainage catheters.

Infections and inflammatory conditions, including spontaneous bacterial peritonitis and peritoneal inflammation, further contribute to acute hospital admissions and procedural interventions. Kidney disease, affecting more than 850 million people worldwide, also increases fluid retention risk and worsens ascites severity when combined with hepatic or cardiac dysfunction.

Overall, liver cirrhosis remains the dominant driver of the ascites market due to its high global prevalence and progressive nature, while malignant ascites represents a smaller but clinically intensive segment characterized by frequent procedures, rapid disease progression, and strong reliance on supportive and palliative care services.

 

Repeat Drainage Still Anchors Treatment Revenue

Large-volume paracentesis remains the standard procedure for large, recurrent or refractory ascites. Current guidelines recommend human albumin after more than five litres of fluid are removed, commonly at eight grams of albumin for each litre extracted. 

A single treatment episode can involve imaging, a drainage kit, clinician time, fluid analysis, albumin and post-procedure monitoring. Because the fluid often returns, the same patient may generate multiple episodes over several months. This recurring model sustains demand for hospital procedures and supportive products even when the underlying liver condition cannot be reversed.

Repeated drainage also creates the main treatment gap. Frequent hospital visits interrupt work, travel and daily activities. Rapid fluid removal can contribute to low blood pressure, kidney dysfunction, sodium imbalance and faster fluid reaccumulation. Albumin reduces part of this risk, but it adds procurement cost and infusion requirements. 

Diuretics and sodium restriction remain the usual starting point. Their commercial value is limited by generic competition and by declining effectiveness or tolerability as liver and kidney function worsen. Albumin holds a stronger hospital position because its use is tied to large-volume drainage and selected cirrhosis complications rather than routine outpatient prescribing. 

TIPS offers a higher-value alternative for selected patients by lowering portal pressure. FDA’s review of the treatment landscape cited efficacy of approximately 45%–63%. However, many patients are unsuitable because of hepatic encephalopathy, active infection, kidney decline, cardiac dysfunction, pulmonary hypertension or advanced liver impairment. 

TIPS therefore expands interventional-radiology activity without replacing paracentesis across the full refractory population. Hospitals with experienced hepatology and interventional teams are better positioned to capture this segment.

Transplantation remains the only treatment that addresses the underlying liver failure and prevents cirrhotic ascites from recurring in eligible patients. The United States performed a record 12,344 liver transplants in 2025, nearly 8% more than in 2024. This included 709 living-donor procedures, representing a 17% annual increase. 

 

FDA Approval Creates a New Implantable Device Segment

The most significant recent market event was FDA approval of Sequana Medical’s alfapump on December 20, 2024. It is approved for adults with recurrent or refractory ascites caused by liver cirrhosis. FDA had granted the system Breakthrough Device status in January 2019. 

The implanted pump moves fluid gradually from the abdominal cavity into the bladder, where it leaves the body through urination. This model converts periodic high-volume hospital drainage into continuous fluid management for selected patients.

The POSEIDON pivotal cohort provides the main evidence for adoption. Among 40 evaluable patients at six months, 73.1% no longer required therapeutic paracentesis. The median monthly paracentesis rate fell by 100%, while 77% of patients achieved at least a 50% reduction. At 24 months, 60.5% remained free from therapeutic paracentesis. 

Physical-health scores improved by an average of 6.4 points. This exceeded the two-point minimum clinically important difference used in the FDA review. Approximately 61.5% of treated patients achieved a clinically meaningful improvement, while participants reported about 10 additional “good health days” per month related to ascites symptoms and management. 

Adoption will depend on patient selection and center capability. FDA identified infection, acute kidney injury, implant-site problems and possible device removal as important risks. The system is also considered unsafe for MRI examinations. 

In the six-month POSEIDON evidence used for FDA’s patient-preference assessment, the observed rate of a minor procedure such as revision or removal was 20%. Serious acute kidney injury or infection requiring hospitalization occurred at a rate of 22.5%. The device therefore competes on reducing repeated drainage and increasing symptom-controlled days, rather than acting as a low-risk substitute for routine paracentesis. 

Sequana is initially targeting 90 US liver-transplant centers. Its estimate of more than 70,000 US patients with recurrent or refractory ascites and a market opportunity above USD 2 billion is a company projection rather than an independently validated market forecast. Actual penetration will depend on hospital approval, surgeon training, safety monitoring, reimbursement verification and evidence from wider commercial use. 

 

Regional Growth Will Follow Burden, Reimbursement and Specialist Capacity

North America currently offers the clearest path for premium device growth. FDA approval, procedure coding, an inpatient add-on payment and a concentrated transplant-center network are in place. The region also has extensive hospital claims infrastructure that can measure paracentesis frequency, admissions and post-implant outcomes. 

FDA’s review included Medicare claims for 701 patients aged 65 or older with refractory ascites between 2017 and 2020. Within this selected cohort, 68.9% experienced an inpatient hospitalization within six months, 82.2% within 12 months and 88.7% within 24 months. These figures are not national prevalence estimates, but they illustrate the high resource use associated with advanced ascites. 

Europe has longer clinical experience with alfapump and a CE-marked device pathway. Adoption still depends on country-level reimbursement, health technology assessments and hospital budgets. Standard care remains heavily based on generic diuretics, albumin, paracentesis and selective TIPS. 

Asia carries the largest absolute chronic-liver-disease burden. However, access to imaging, albumin, interventional radiology and transplantation differs widely. Near-term treatment volume is likely to remain concentrated in drainage, generic medicines and hospital supportive care. Premium implantable systems are more likely to enter through large tertiary liver centers with the capacity to manage infection, kidney function and post-implant follow-up. 

 

Major Companies Compete Across Separate Treatment Pathways

The ascites market does not have one company controlling diagnosis, medication, drainage and advanced intervention. Competition is divided among albumin manufacturers, catheter suppliers, implantable-device developers and interventional-radiology companies. Each group earns revenue at a different stage of disease, making hospital access and inclusion in treatment pathways more important than broad product portfolios.

Sequana Medical has introduced the first FDA-approved implantable pump (alfapump) for continuous management of recurrent or refractory cirrhotic ascites, with early commercial use beginning in late 2025 at select liver transplant centers. Its impact is currently limited to high-risk patients, with clinical value assessed through reduced paracentesis frequency and fewer hospital visits rather than broad procedural adoption. In parallel, BD’s PeritX catheter system, Merit Medical’s Aspira system, and Rocket Medical’s drainage solutions are expanding home- and community-based ascites management, primarily in malignant and chronic cases, where recurring consumable use drives steady revenue. W. L. Gore & Associates remains positioned in the high-acuity segment through its TIPS endoprosthesis, used for refractory portal hypertension cases that do not respond to conventional therapy.

Overall, the market is shifting toward reducing hospital-based fluid removal through implantable pumps and home drainage systems, while still relying on established interventional procedures like paracentesis and TIPS for advanced disease. Growth is increasingly driven by recurring consumables, long-term drainage management, and procedure avoidance rather than one-time interventions, with each company occupying a distinct role across severity levels and care settings.

Albumin remains essential in ascites care because it is routinely given after large-volume paracentesis to prevent circulatory complications. Grifols supplies ALBUTEIN in multiple strengths, including a 25% formulation used in cirrhotic ascites. CSL Behring markets albumin products such as ALBUMINAR and ALBURX, while Bio Products Laboratory offers ALBUMINEX 5% and 25%. These companies compete mainly on supply reliability, plasma availability, and hospital contracts, as demand is closely tied to ongoing paracentesis use.

 

Analyst Perspective: Revenue Is Moving From Fluid Removal to Fluid-Controlled Care

The Global Ascites Market is projected to increase from USD 1.56 billion in 2025 to USD 2.46 billion by 2032, expanding at a CAGR of 6.7%. The main growth mechanism is not a rapid increase in newly diagnosed ascites alone. Revenue expands because advanced patients return repeatedly for drainage, albumin administration, imaging, infection testing and hospital monitoring.

Paracentesis will remain the main treatment and revenue driver in ascites care because it is widely available, provides fast symptom relief, and continues to generate demand for imaging, consumables, and albumin. As a result, new technologies are being added to existing hospital workflows rather than replacing them.

The market is slowly shifting toward longer-term fluid control. Sequana Medical is leading early adoption of its FDA-approved alfapump in specialized liver centers, while BD, Merit Medical, and Rocket Medical are expanding in home drainage through catheter-based systems supported by recurring consumable sales.

However, growth of advanced devices is limited by safety concerns, procedural complexity, and reimbursement challenges. Albumin demand remains steady and closely linked to paracentesis volumes. TIPS and liver transplantation continue to serve a small, highly selected patient group, meaning new innovations mainly complement rather than replace standard drainage care.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.56 Billion
Revenue Forecast in 2032	USD 2.46 Billion
Overall Growth Rate	CAGR of 6.7% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Disease Type, By End User, By Geography
By Treatment Type	Diuretics, Large-Volume Paracentesis, Albumin Therapy, Transjugular Intrahepatic Portosystemic Shunt [TIPS], Implantable Pump Systems, Indwelling Drainage Catheters, Liver Transplantation, Investigational Therapies
By Disease Type	Cirrhotic Ascites, Malignant Ascites, Cardiac Ascites, Renal Ascites, Other Ascites Conditions
By End User	Hospitals, Liver Transplant Centers, Specialty Clinics, Ambulatory and Outpatient Care Centers, Home-Care Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising burden of decompensated liver cirrhosis and refractory ascites; recurring demand for paracentesis, albumin and hospital monitoring; increasing adoption of implantable pumps and home-drainage systems; expanding need for supportive care in malignant, cardiac and renal ascites
Customization Option	Available upon request